The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | The future of TRK inhibitors in lung cancer treatment
Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, looks ahead to the next generation of tropomyosin receptor kinase (TRK) inhibitors and their role in lung cancer treatment. TRK inhibitors are used to treat non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase (NTRK) or neuregulin-1 (NRG1) gene fusions. The rarity of these oncogenic drivers presents a challenge for sufficient research. While it is known that resistance mutations to first line treatments, larotrectinib and entrectinib can typically be treated with repotrectinib. However, there is even less opportunity to research potential on-target resistance to repotrectinib. The rarity of these populations also poses a challenge to researching the combination of a TKI with platinum-based doublet chemotherapy in the first line setting, which has been utilized in other oncogenic subsets of lung cancer. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
